Towards Healthcare
APAC Cell and Gene Therapy Market to Grow at 23.20% CAGR till 2034

APAC Cell and Gene Therapy Market Sees Rapid Expansion Trends

Projections indicate that, APAC cell and gene therapy industry is projected to rise from USD 9.93 billion in 2024 to USD 80.01 billion by 2034, reflecting a CAGR of 23.20% over the next decade. A surge in wider demand for advanced therapies due to rising severe concerns, like cancers, rare disorders, is supporting the overall market growth. China dominated the market due to the presence of robust government support and escalating R&D investments.

Content

  • Insight Code: 6279
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The APAC cell and gene therapy market is valued at USD 12.11 billion in 2025 and is on track to reach USD 80.01 billion by 2034, witnessing a steady CAGR of 23.20% during the forecast span.

China is currently leading the APAC cell and gene therapy market share 35% due to the increasing patient population & supportive government provision.

Some key players include JW Therapeutics, Legend Biotech, CARsgen Therapeutics, Takeda Pharmaceutical Company, and Daiichi Sankyo.

NICER method, CRISPR-Cas9, Allele-specific editing, and TALENs are certain gene editing technologies used in Japan.

ISCT, PMDA, NMPA, HSA, MFDS, IMAPAC, ITA, PPD, NIH, PIB.
Any Questions